9
Jan
2022
Beware of the Expert Fallacy, But Don’t Fall Into The Cynicism Trap
In December, a team led by two University of Pennsylvania scholars, psychologist Angela Duckworth (best known as author of Grit) and behavioral economist Katy Milkman published in Nature the results of a colossal study on behavior change. The researchers evaluated the impact of a huge range of behavioral interventions – 54 – that were thought to potentially influence gym attendance... Read More
6
Jan
2022
Biotech’s Candle Burns Bright in the Dark
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jan
2022
The Omicron Wave: A Review of the Research on Spread and Severity
The vast majority of people in the US have at least partial immunity to many forms of SARS-CoV-2, either from prior infection, vaccination, or both. The past few weeks have shown us that the Omicron variant transmits faster than any of its predecessors. That essentially guarantees that the unvaccinated plus early vaccinees (last dose/boost more than 6 months ago) will... Read More
5
Jan
2022
RNA Editing Seeks Its Place in the Gene Editing World
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2022
The Future is Simple: How the Genetic Revolution is Making Old Modalities Stronger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2021
A Doctor’s View From the Front Line of the Omicron Wave
My phone buzzed with alerts about record-setting case numbers as I rushed between patients. A pile of tiny bottles with swabs floating in pink liquid accumulated while awaiting PCR testing. Patients with coughs and sniffles lined up outside the door, waiting to be seen. My shift as an internal medicine physician yesterday in MGH Chelsea’s urgent care facility reminded me... Read More
23
Dec
2021
Pfizer, Merck Get COVID Drugs OK’d, Sanofi Buys Amunix, and a New PCSK9 Contender
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Dec
2021
Improving Health and Wellness in 2022
As we start to think about 2022 and improving our health and wellness in the New Year, we make ambitious resolutions and urgently try to identify the optimal diet and best exercise program to achieve our health goals. Stop Searching For The One As intuitive as this approach sounds, it’s almost certainly the wrong mindset. What behavior change experts, including... Read More
20
Dec
2021
Controlling COVID in 2022: Masks, Treatments and Fast, Frequent Testing
Over the past week I have been reflecting on what we know now, two years into a seemingly unending pandemic. One of the biggest failures has been with testing. At first, our only effective defenses were masking and social distancing. We were slow to ramp up testing, unable to give most people the timely information they could use to isolate... Read More
20
Dec
2021
Physician-Scientist-Biotech VC: Vineeta Agarwala on The Long Run
Today’s guest on The Long Run is Vineeta Agarwala. Vineeta is a general partner with Andreesen Horowitz’s bio fund. Vineeta has spent a lot of time on the front lines of an explosion in biological data, and efforts to analyze it to develop better therapeutics, diagnostics and digital health applications. Before coming to A16Z, she worked at GV and Flatiron... Read More
16
Dec
2021
JPM Goes Virtual, Pfizer Acquires Arena, & Arc Reimagines the Scientific Enterprise
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Dec
2021
Verge Genomics Gets $98M to Take ALS Drug to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2021
The Long War
I think I have seen enough. We cannot fight an exponential rise with linear thinking and processes. And yet, this is what we keep doing. On that optimistic note, some background for those of you who are new to my cranky musings. As many of you know, I wrote here on Nov. 26 about the emergence of Omicron as an... Read More
14
Dec
2021
The Other Side of The Story: Vaccines Must Produce Both Antibodies and T cell Immunity
It’s time to include T cells in the fight against COVID-19. The scientific community brought novel vaccines to the world in less than a year. That heroic work saved millions of lives. These vaccines were designed specifically to induce antibodies that target the spike protein and disable the virus, blocking it from entering the ACE2 receptor on cells. Like other... Read More
9
Dec
2021
A Missed Opportunity for Grownups
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Dec
2021
SQZ Shows Promise With HPV+ Cancer Vaccine in Early Solid Tumor Clinical Trial
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Dec
2021
Three Core Questions Underlying Durable Behavior Change
Each of us would be happier and healthier if we could adopt and maintain healthier behaviors. Many of us – including providers, organizational heads, community leaders, parents – hope to cultivate healthier behavior in others. The difficulty we experience attaining these common goals reflects three underlying questions around behavior change. Is the most effective locus of intervention the individual... Read More
8
Dec
2021
Newpath Partners Secures $350M for Startups Working on Hard Science Problems
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2021
Targeted Small Molecule Protein Degraders: Nello Mainolfi on The Long Run
Today’s guest on The Long Run is Nello Mainolfi. Nello is the president and CEO of Cambridge, Mass.-based Kymera Therapeutics. Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of... Read More
5
Dec
2021
Corporate Health and Wellness Has New Urgency And Vision
Like no other event in our collective experience, the pandemic reminded us of the need for an integrative view of wellbeing beyond traditional measures of physical health. Focusing exclusively on cholesterol level and bone density, for example, would be hopelessly inadequate for the needs of today. I continued to be haunted by Zak Kohane’s description of the many children’s hospitals... Read More